Table 4.
The sensitivities and specificities of mSFRP2 alone, mSDC2 alone and SpecColon test for detecting SP, AA and CRC in the validation cohort
| Number (n) | Age (years) | Gender (%) | Sensitivities (%) | ||||
|---|---|---|---|---|---|---|---|
| Mean (Min-Max) | Male | Female | mSFRP2 | mSDC2 | SpecColon | ||
| CRC | 58 | 61.0 (20-79) | 62.1 | 37.9 | 77.6 | 86.2 | 89.7 |
| 0 | 2 | 63.5 (57-70) | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 |
| I | 9 | 71.7 (57-79) | 55.6 | 44.4 | 88.9 | 77.8 | 88.9 |
| II | 15 | 63.1 (36-79) | 80.0 | 20.0 | 80.0 | 93.3 | 93.3 |
| III | 18 | 55.1 (20-72) | 55.6 | 44.4 | 77.8 | 77.8 | 83.3 |
| IV | 5 | 60.4 (50-78) | 100.0 | 0.0 | 80.0 | 100.0 | 100.0 |
| Unknown | 9 | 58.7 (22-78) | 33.3 | 66.7 | 66.7 | 100.0 | 100.0 |
| Polyp | |||||||
| AA | 13 | 66.9 (48-92) | 69.2 | 30.8 | 61.5 | 46.2 | 61.5 |
| SP | 20 | 55.8 (31-77) | 50.0 | 50.0 | 15.0 | 15.0 | 20.0 |
| Specificities (%) | 38 | 44.4 (22-77) | 55.3 | 44.7 | 89.5 | 97.4 | 89.5 |